Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis.

Scott Kopetz, George Laliotis, Maen Abdelrahim et al. Jun 01, 2026 pp. 11177-11177 10.1200/jco.2026.44.16_suppl.11177

11177 Background: Early detection of recurrence after curative-intent treatment is a critical priority, traditional imagin...

Clinician-facilitated cascade genetic testing among first-, second-, and third-degree relatives.

Steve Lopez, Lauren Davis Rivera, Max Kirby et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13584

e13584 Background: Cascade genetic testing enables identification of individuals at increased hereditary cancer risk, yet...

Survivorship-focused content at the American Society of Clinical Oncology (ASCO) 2022-2024 annual meetings.

Lauren Rynar, Sandra Naaman, Benjamin Bates et al. Jun 01, 2026 pp. 1671-1671 10.1200/jco.2026.44.16_suppl.1671

1671 Background: Survivorship is a core component of comprehensive cancer care yet its representation in major oncology sc...

Impact of medically tailored meals plus nutrition counseling on treatment adherence in vulnerable lung cancer patients: Results from NutriCare randomized controlled trial.

Zhongyao Li, Kenneth Chui, Gail Rogers et al. Jun 01, 2026 pp. 1672-1672 10.1200/jco.2026.44.16_suppl.1672

1672 Background: This study aims to evaluate the impact of a Food is Medicine intervention on reducing treatment interrupt...

Mortality trends of brain tumors complicated by respiratory failure: National patterns and forecasted burden through 2035.

Diljot Singh, Ali Zubair, Kanchan Chaudhary et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14050

e14050 Background: Acute respiratory failure (ARF) represents the leading indication for intensive care unit (ICU) admissi...

Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: Update of a prospective single center, single-arm phase II clinical trial.

Huijuan Yang, Yi Fu, Shuai Liu et al. Jun 01, 2026 pp. 5586-5586 10.1200/jco.2026.44.16_suppl.5586

5586 Background: Ovarian clear cell carcinoma (OCCC) is a histologically aggressive subtype of epithelial ovarian cancer w...

Concordance of tissue and plasma NGS in early-stage non–small cell lung cancer.

Juhi Gor, Teri Hill, Mary M. Pasquinelli et al. Jun 01, 2026 pp. 11071-11071 10.1200/jco.2026.44.16_suppl.11071

11071 Background: Comprehensive molecular profiling is standard of care for patients with advanced non-small cell lung can...

National characteristics of Kaposi sarcoma–related hospitalizations and in-hospital outcomes in the United States, 2018–2022.

Sheldon Rankine, Jason Ta, Ramaditya Srinivasmurthy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23529

e23529 Background: Kaposi sarcoma (KS) is a rare malignancy predominantly affecting immunocompromised populations and may...

Role of circRNA in modulating tumor microenvironment: From mycobacterial infection to lung cancer.

Yen-Han Tseng, Feng Jia-Yih, Yuh-Min Chen Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20025

e20025 Background: Tuberculosis (TB) is significantly associated with an increased risk of lung cancer, yet the underlying...

Expanded germline genetic testing of patients with hematologic malignancies to identify high proportion with hereditary cancer predisposition.

Ozge Ceyhan-Birsoy, Lauren Gabriele Banaszak, Elise Fiala et al. Jun 01, 2026 pp. 10612-10612 10.1200/jco.2026.44.16_suppl.10612

10612 Background: Identifying hereditary cancer predisposition in patients with hematologic malignancies is critical for t...

Conditional cancer-specific survival analysis by HPV status in oropharyngeal squamous cell carcinoma.

Andrew Chen, Irene Wang, Brendon Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18128

e18128 Background: HPV-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) is known to be associated with increa...

Efficacy and safety of maintenance therapy in unresectable locally advanced esophageal squamous cell carcinoma.

Chuanyu You, Yan Gui Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16123

e16123 Background: Esophageal cancer is an aggressive malignancy and the seventh leading cause of cancer-related mortality...

National implementation of electronic patient-reported outcomes (ePROs) for remote symptom monitoring in oncology: The OncoPRO initiative.

Ethan Basch, Jennifer Jansen, Philip M. Carr et al. Jun 01, 2026 pp. 1571-1571 10.1200/jco.2026.44.16_suppl.1571

1571 Background: Remote symptom monitoring with electronic patient-reported outcomes (PROs) during cancer care improves qu...

Organ- and histology-specific molecular and immune landscape of metastatic breast cancer.

Guilherme Nader Marta, Sachin Kumar Deshmukh, Kristina Fanucci et al. Jun 01, 2026 pp. 1024-1024 10.1200/jco.2026.44.16_suppl.1024

1024 Background: Invasive lobular carcinoma (ILC) is a distinct breast cancer (BC) subtype with dissemination patterns dif...

Neoadjuvant chemotherapy followed by transanal endoscopic surgery (TES) and selective chemoradiation or total mesorectal excision (TME) for early-stage rectal cancer: The Ottawa Hospital experience.

Mohammed Al Darai, Nasra Al-Busaidi, Husein Moloo et al. Jun 01, 2026 pp. 3627-3627 10.1200/jco.2026.44.16_suppl.3627

3627 Background: Organ-sparing therapy for early-stage rectal cancer may avoid permanent ostomy or functional disturbances...

Taxane-based chemotherapy with or without platinum agents in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

Anas Al-sadi, Muhammad Shaheer Mannan, Syed Mohamin Abbas Shah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17079

e17079 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge in later-line s...

A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from the adenoid cystic cohort.

Katharine Andress Rowe Price, Nathan Foster, Erik Asmus et al. Jun 01, 2026 pp. 6123-6123 10.1200/jco.2026.44.16_suppl.6123

6123 Background: Pemetrexed (PTX) is safe and tolerable with responses reported in pts with R/M SGC. Given enhanced respon...

Personality-driven roles of large language models for axillary surgery recommendation.

Claire Dvorak, Tomas Dvorak, Jeffrey R. Smith et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13703

e13703 Background: Large language models (LLMs) are increasingly evaluated for clinical decision support. Inclinical pract...

Interim analysis of efficacy and safety of adjuvant donafenib plus transarterial chemoembolization in patients with hepatocellular carcinoma and high-risk features after curative resection.

Baoluhe Zhang, Xiaokun Chen, Yonghui Ma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16251

e16251 Background: Postoperative recurrence remains a major challenge in hepatocellular carcinoma (HCC), particularly amon...

Clinical implementation of an online family cascade genetic testing platform: The Preventive Risk Outreach and Cascade Testing (PROACT) initiative.

Jennifer Lee Caswell-Jin, Rachel Hodan, Sonia Rios-Ventura et al. Jun 01, 2026 pp. 10609-10609 10.1200/jco.2026.44.16_suppl.10609

10609 Background: Cascade genetic testing of relatives in families with hereditary cancer susceptibility is an essential s...

Effect of immune checkpoint inhibitor infusion timing on overall survival in non–small cell lung cancer: A real-world retrospective study.

Nency Ganatra, Ahmed Abdelhakeem, Pragya Jain et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20595

e20595 Background: Circadian regulation of immune function has been proposed as a modifier of immune checkpoint inhibitor...

Incidence, spectrum, and clinical outcomes of immune-related adverse events in 227 consecutive patients treated with immune checkpoint inhibitors: An Indian real-world cohort.

Dr. Sakina Mankada, Krishna Ratanchandani, Dr. Vaishnavi Joshi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23392

e23392 Background: Real-world safety data on immune checkpoint inhibitors (ICIs) from low- and middle-income countries rem...

National trends in sudden cardiac death among patients with hematologic malignancies in the United States: CDC analysis, 1999–2023.

Steve Oguguo Nwokeocha, Noor Fatima, Huzaifa Sabir Nawaz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18622

e18622 Background: Sudden cardiac death (SCD) is a significant cause of mortality and this risk could be more pronounced i...

Late infectious complications after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphomas (LCBL): Real-world predictors and outcomes.

Daniel E. Goyco Vera, Omer Abdrabbuh, Fatima Massare Somers et al. Jun 01, 2026 pp. 7022-7022 10.1200/jco.2026.44.16_suppl.7022

7022 Background: CD19-directed CAR-T therapy is a curative option for patients (pts) with relapsed/refractory (R/R) LBCL....

Prognostic and therapeutic implications of HRR gene mutations in non-cutaneous melanoma: Association with anti-PD-1 efficacy.

Yue Yang, Yuqing Su, Chuanliang Cui et al. Jun 01, 2026 pp. 9537-9537 10.1200/jco.2026.44.16_suppl.9537

9537 Background: Homologous recombination deficiency (HRD) describes a tumor cell state characterized by impaired DNA doub...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page